ProKidney Corp. (PROK)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
ProKidney Corp. (PROK) trades at $2.14 with AI Score 51/100 (Hold). ProKidney Corp. is a clinical-stage biotechnology company focused on developing cellular therapy candidates for kidney disease. Market cap: 602215945, Sector: Healthcare.
Last analyzed: Feb 8, 2026ProKidney Corp. (PROK) Healthcare & Pipeline Overview
ProKidney Corp. pioneers cellular therapy for kidney disease, with Renal Autologous Cell Therapy (REACT) in Phase III trials, offering a transformative treatment for diabetic kidney disease and congenital anomalies, positioning the company at the forefront of regenerative medicine.
Investment Thesis
ProKidney Corp. presents a notable research candidate due to its innovative approach to treating kidney disease with Renal Autologous Cell Therapy (REACT). The Phase III development program for diabetic kidney disease represents a significant near-term catalyst, with positive trial results potentially leading to regulatory approval and commercialization. The company's focus on cellular therapy offers a differentiated approach compared to traditional treatments, potentially capturing a significant share of the kidney disease market. With a market capitalization of $0.53 billion, ProKidney offers upside potential if REACT proves successful. Key value drivers include successful clinical trial outcomes, regulatory approvals, and strategic partnerships. The ongoing Phase II and Phase I trials for other kidney-related conditions provide additional growth opportunities, expanding the potential market for ProKidney's therapies.
Based on FMP financials and quantitative analysis
Key Highlights
- Market Cap of $0.53B reflects investor valuation of ProKidney's potential in the biotechnology space.
- P/E ratio of -3.55 indicates that the company is currently unprofitable, common for clinical-stage biotech companies.
- Gross Margin of -87.9% reflects the high costs associated with research and development in the biotechnology industry.
- Beta of 1.82 suggests that the stock is more volatile than the market average.
- Lead candidate REACT is in Phase III development for diabetic kidney disease, representing a significant milestone.
Competitors & Peers
Strengths
- Innovative cellular therapy approach.
- Lead candidate in Phase III development.
- Strong intellectual property protection.
- Experienced management team.
Weaknesses
- Clinical-stage company with no current revenue.
- High research and development costs.
- Dependence on clinical trial outcomes.
- Negative profit and gross margins.
Catalysts
- Upcoming: Data readout from Phase III clinical trials for REACT in diabetic kidney disease.
- Upcoming: Regulatory submissions for REACT in key markets.
- Ongoing: Enrollment and progress in Phase II and Phase I clinical trials.
- Ongoing: Potential for strategic partnerships and collaborations.
Risks
- Potential: Clinical trial failures or delays.
- Potential: Regulatory rejection of REACT.
- Potential: Competition from other therapies.
- Ongoing: High cash burn rate and need for additional funding.
- Ongoing: Dependence on key personnel.
Growth Opportunities
- Successful Completion of Phase III Trials: The successful completion of Phase III clinical trials for REACT in diabetic kidney disease represents a major growth opportunity for ProKidney. Positive trial results could lead to regulatory approval and commercialization, opening up a significant market for the company. The timeline for this opportunity is dependent on the trial outcomes, with potential for data readout in the near term.
- Expansion into Congenital Anomalies of the Kidney and Urinary Tract (CAKUT): ProKidney's Phase I clinical trial for patients with CAKUT represents another growth opportunity. CAKUT affects a significant number of children and can lead to CKD. Successful development of REACT for CAKUT could expand ProKidney's market reach and address an unmet medical need. The timeline for this opportunity is dependent on the Phase I trial outcomes.
- Strategic Partnerships and Collaborations: ProKidney can pursue strategic partnerships and collaborations with pharmaceutical companies and research institutions to accelerate the development and commercialization of REACT. These partnerships could provide access to additional funding, expertise, and market reach. The timeline for this opportunity is ongoing, as ProKidney can actively seek out and establish partnerships.
- Expansion into New Geographic Markets: Following regulatory approval in key markets, ProKidney can expand its commercial operations into new geographic regions. This could involve establishing sales and marketing infrastructure or partnering with local distributors. The timeline for this opportunity is dependent on regulatory approvals and market access strategies.
- Development of Next-Generation Cellular Therapies: ProKidney can leverage its expertise in cellular therapy to develop next-generation therapies for kidney disease. This could involve exploring new cell types, delivery methods, or combination therapies. The timeline for this opportunity is longer-term, as it requires further research and development.
Opportunities
- Successful commercialization of REACT.
- Expansion into new indications and markets.
- Strategic partnerships and collaborations.
- Advancements in cellular therapy technology.
Threats
- Clinical trial failures.
- Regulatory hurdles.
- Competition from other therapies.
- Changes in healthcare reimbursement policies.
Competitive Advantages
- Proprietary cellular therapy technology.
- Patent protection for REACT.
- Clinical trial data demonstrating safety and efficacy.
- First-mover advantage in the autologous cell therapy space for kidney disease.
About PROK
Founded in 2015 and headquartered in Winston-Salem, North Carolina, ProKidney Corp. is a clinical-stage biotechnology company dedicated to developing innovative cellular therapies for the treatment of kidney disease. The company's primary focus is on Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture designed to treat chronic kidney disease (CKD). REACT is currently undergoing a Phase III development program for moderate to severe diabetic kidney disease, representing a significant unmet medical need. Additionally, ProKidney is conducting Phase II clinical trials for diabetic kidney disease and Phase I clinical trials for patients with congenital anomalies of the kidney and urinary tract (CAKUT), demonstrating a broad commitment to addressing various kidney-related conditions. ProKidney's approach leverages the patient's own cells to regenerate kidney tissue, potentially offering a more effective and less invasive alternative to traditional treatments like dialysis and kidney transplantation. The company's focus on cellular therapy positions it within the rapidly evolving field of regenerative medicine, with the potential to disrupt the treatment paradigm for kidney disease. With a team of 204 employees, ProKidney is striving to improve the lives of patients suffering from kidney disease through innovative cellular therapies.
What They Do
- Develops Renal Autologous Cell Therapy (REACT) for kidney disease.
- Conducts Phase III clinical trials for REACT in diabetic kidney disease.
- Conducts Phase II clinical trials for REACT in moderate to severe diabetic kidney disease.
- Conducts Phase I clinical trials for REACT in patients with congenital anomalies of the kidney and urinary tract (CAKUT).
- Focuses on regenerative medicine approaches to treat kidney disease.
- Aims to provide alternatives to dialysis and kidney transplantation.
Business Model
- Develops and patents cellular therapy technologies.
- Conducts clinical trials to demonstrate safety and efficacy.
- Seeks regulatory approval for its therapies.
- Commercializes its therapies through direct sales and marketing or partnerships.
Industry Context
ProKidney operates in the biotechnology industry, specifically focusing on cellular therapies for kidney disease. The market for kidney disease treatment is substantial and growing, driven by the increasing prevalence of diabetes and hypertension, major risk factors for CKD. The competitive landscape includes companies developing pharmaceuticals and medical devices for kidney disease, as well as other biotechnology companies exploring regenerative medicine approaches. ProKidney's focus on autologous cell therapy differentiates it from competitors, potentially offering a more personalized and effective treatment option. The global kidney dialysis market is projected to reach billions of dollars, highlighting the significant market opportunity for innovative therapies like REACT.
Key Customers
- Patients with diabetic kidney disease.
- Patients with congenital anomalies of the kidney and urinary tract (CAKUT).
- Healthcare providers specializing in nephrology.
- Hospitals and dialysis centers.
Financials
Chart & Info
ProKidney Corp. (PROK) stock price: $2.14 (-0.09, -4.04%)
Latest News
-
Aquestive Therapeutics (AQST) Reports Q4 Loss, Misses Revenue Estimates
Zacks · Mar 4, 2026
-
Simulations Plus, FB Financial And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
benzinga · Jul 15, 2025
-
12 Health Care Stocks Moving In Thursday's Intraday Session
benzinga · Jul 10, 2025
-
12 Health Care Stocks Moving In Thursday's Pre-Market Session
benzinga · Jul 10, 2025
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for PROK.
Price Targets
Wall Street price target analysis for PROK.
MoonshotScore
What does this score mean?
The MoonshotScore rates PROK's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Latest News
Aquestive Therapeutics (AQST) Reports Q4 Loss, Misses Revenue Estimates
Simulations Plus, FB Financial And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Thursday's Intraday Session
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Latest ProKidney Corp. Analysis
Common Questions About PROK
What does ProKidney Corp. do?
ProKidney Corp. is a clinical-stage biotechnology company focused on developing cellular therapies for the treatment of kidney disease. Its lead product candidate, Renal Autologous Cell Therapy (REACT), is an autologous cell therapy currently in Phase III clinical development for the treatment of diabetic kidney disease. The company's goal is to provide a transformative treatment option for patients with chronic kidney disease, potentially reducing or eliminating the need for dialysis and kidney transplantation. ProKidney is also exploring the use of REACT in other kidney-related conditions, such as congenital anomalies of the kidney and urinary tract (CAKUT).
Is PROK stock worth researching?
PROK stock is a speculative investment opportunity given its clinical-stage nature and lack of current revenue. The potential success of REACT in Phase III trials is a major value driver, but also a significant risk. Investors should carefully consider their risk tolerance and investment horizon before investing in PROK. While the potential upside is substantial if REACT is approved, the company's negative profit margin and reliance on future funding present challenges. A positive outcome in the Phase III trials could significantly increase the stock price, but failure could lead to substantial losses.
What are the main risks for PROK?
The main risks for ProKidney Corp. include the inherent risks associated with clinical-stage biotechnology companies. Clinical trial failures or delays could significantly impact the company's prospects. Regulatory hurdles and potential rejection of REACT by regulatory agencies pose another significant risk. Competition from other therapies and changes in healthcare reimbursement policies could also affect the company's commercial success. Additionally, ProKidney faces the risk of high cash burn and the need for additional funding to support its ongoing clinical trials and operations.
What are the key factors to evaluate for PROK?
ProKidney Corp. (PROK) currently holds an AI score of 51/100, indicating moderate score. Key strength: Innovative cellular therapy approach.. Primary risk to monitor: Potential: Clinical trial failures or delays.. This is not financial advice.
How frequently does PROK data refresh on this page?
PROK prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven PROK's recent stock price performance?
Recent price movement in ProKidney Corp. (PROK) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Innovative cellular therapy approach.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider PROK overvalued or undervalued right now?
Determining whether ProKidney Corp. (PROK) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying PROK?
Before investing in ProKidney Corp. (PROK), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information based on available company data and AI insights. Clinical trial outcomes are inherently uncertain.